Xilio Therapeutics Inc (NAS:XLO)
$ 1.32 -0.12 (-8.33%) Market Cap: 58.02 Mil Enterprise Value: -3.42 Mil PE Ratio: 0 PB Ratio: 1.74 GF Score: 34/100

Xilio Therapeutics Inc at Citi Virtual Oncology Leadership Summit Transcript

Feb 23, 2023 / 02:00PM GMT
Release Date Price: $3.64 (+2.54%)
Operator

Hello, and welcome to Day 3 of Citi's Oncology Leadership Conference. Delighted to have you with us again. I'm equally delighted to introduce our first speaker, Rene Russo, who is the CEO of Xilio. Now we're at broadchurch here at Citi's Oncology Conference with big hosting companies as large as Genetech Roche, Sanofi, GSK. And now we're down into the smaller names. But we think it's an interesting story and a very interesting technology. So we wanted to be early to highlight it to you.

So unlike the other sessions where many of you are very familiar with the underlying technology. What we've done is allocate some time for Rene, who's the CEO of Xilio to really provide some background of the company, and then we'll have time for Q&A afterwards, which I'll moderate. As always, if you do have a question you'd like me to ask Rene then please e-mail me, andrew.baumciti.com, and I'm more than happy to ask on your behalf. Anyway. With that, Rene, over to you, and thank you for joining us today.

Rene Russo
Xilio Therapeutics, Inc. - CEO & Director

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot